Effects of flavonoids on glycosaminoglycan synthesis: Implications for substrate reduction therapy in Sanfilippo disease and other mucopolysaccharidoses

Metabolic Brain Disease

Volumn 26, Issue 1, 2011, Pages 1-8

  Kloska, Anna ^a   Jakóbkiewicz Banecka, Joanna ^a   Narajczyk, Magdalena ^a   Banecka Majkutewicz, Zyta ^b   Węgrzyn, Grzegorz ^a  

^a UNIVERSITY OF GDA SK   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Flavonoids; Glycosaminoglycan synthesis; Mucopolysaccharidoses; Substrate reduction therapy

Indexed keywords

APIGENIN; DAIDZEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLAVONOID; GENISTEIN; GLYCOSAMINOGLYCAN; KAEMPFEROL; NARINGENIN; PROTEIN TYROSINE KINASE;

ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; FIBROBLAST; GLYCOSAMINOGLYCAN METABOLISM; HUMAN; HUMAN CELL; MUCOPOLYSACCHARIDOSIS; PROTEIN PHOSPHORYLATION; SANFILIPPO SYNDROME; SANFILIPPO SYNDROME TYPE A; SANFILIPPO SYNDROME TYPE B; SUBSTRATE REDUCTION THERAPY; THERAPY;

EID: 79955100797     PISSN: 08857490     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11011-011-9233-2     Document Type: Article

References (32)

1. A Arfi M Richard C Gandolphe D Scherman 2010 Storage correction in cells of patients suffering from mucopolysaccharidoses types IIIA and VII after treatment with genistein and other isoflavones J Inherit Metab Dis 33 61 67 20084460 10.1007/s10545-009-9029-2 1:CAS:528:DC%2BC3cXisV2qt7k%3D
2. Beck M (2007a) Mucopolysaccharidoses: clinical features and management. In: vom Dahl S, Wendel U, Strohmeyer G (eds) Genetic metabolic disorders: management, costs and sociomedical aspects. Deutscher Arzte-Verlag, Cologne, pp 13-18
3. M Beck 2007 New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy Hum Genet 121 1 22 17089160 10.1007/s00439-006-0280-4 1:CAS:528:DC%2BD2sXhsFCgs7k%3D (Pubitemid 46421136)
4. HE Bulow O Hobert 2006 The molecular diversity of glycosaminoglycans shapes animal development Annu Rev Cell Dev Biol 22 375 407 16805665 10.1146/annurev.cellbio.22.010605.093433 1:CAS:528:DC%2BD28Xht1yjs7jO
5. E de Azambuja PL Bedard T Suter M Piccart-Gebhart 2009 Cardiac toxicity with anti-HER-2 therapies: what have we learned so far? Target Oncol 4 77 88 19418111 10.1007/s11523-009-0112-2
6. D Dziedzic G Wegrzyn J Jakobkiewicz-Banecka 2009 Impairment of glycosaminoglycan synthesis in mucopolysaccharidosis type IIIA cells by using siRNA: a potential therapeutic approach for Sanfilippo disease Eur J Hum Genet 18 200 205 19690584 10.1038/ejhg.2009.144
7. A Friso R Tomanin M Salvalaio M Scarpa 2010 Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II Br J Pharmacol 159 1082 1091 20136838 10.1111/j.1476-5381.2009.00565.x 1:CAS:528:DC%2BC3cXjs1ekt7w%3D
8. J Jakobkiewicz-Banecka A Wegrzyn G Wegrzyn 2007 Substrate deprivation therapy: a new hope for patients suffering from neuronopathic forms of inherited lysosomal storage diseases J Appl Genet 48 383 388 17998597 10.1007/BF03195237 (Pubitemid 350219938)
9. J Jakobkiewicz-Banecka E Piotrowska M Narajczyk S Baranska G Wegrzyn 2009 Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway J Biomed Sci 16 26 19272193 10.1186/1423-0127-16-26
10. X Kaidonis WC Liaw AD Roberts M Ly D Anson S Byers 2009 Gene silencing of EXTL2 and EXTL3 as a substrate deprivation therapy for heparan sulphate storing mucopolysaccharidoses Eur J Hum Genet 18 194 199 19690583 10.1038/ejhg.2009.143
11. M Kato S Takeda S Ogawara S Takayama 1995 Effect of levofloxacin on glycosaminoglycan and DNA synthesis of cultured rabbit chondrocytes at concentrations inducing cartilage lesions in vivo Antimicrob Agents Chemother 39 1979 1983 8540702 1:CAS:528:DyaK2MXnvVygsbw%3D
12. CB Klein AA King 2007 Genistein genotoxicity: critical considerations of in vitro exposure dose Toxicol Appl Pharmacol 224 1 11 17688899 10.1016/j.taap.2007.06.022 1:CAS:528:DC%2BD2sXhtVOgu7bF (Pubitemid 47404623)
13. SJ Kwack KB Kim HS Kim KS Yoon BM Lee 2009 Risk assessment of soybean-based phytoestrogens J Toxicol Environ Health A 72 1254 1261 20077194 10.1080/15287390903212212 1:CAS:528:DC%2BD1MXhsValsLvN
14. T Li R Perez-Soler 2009 Skin toxicities associated with epidermal growth factor receptor inhibitors Target Oncol 4 107 119 19452131 10.1007/s11523-009- 0114-0
15. J Li JC Richards 2010 Functional glycomics and glycobiology: an overview Methods Mol Biol 600 1 8 19882117 10.1007/978-1-60761-454-8-1 1:CAS:528:DC%2BC3cXlvFSgsw%3D%3D
16. N Li JH Liu J Zhang BY Yu 2008 Comparative evaluation of cytotoxicity and antioxidative activity of 20 flavonoids J Agric Food Chem 56 3876 3883 18433100 10.1021/jf073520n 1:CAS:528:DC%2BD1cXkvF2murg%3D (Pubitemid 351860197)
17. M Malinowska FL Wilkinson W Bennett, et al. 2009 Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice Mol Genet Metab 98 235 242 19632871 10.1016/j.ymgme.2009.06.013 1:CAS:528: DC%2BD1MXht1GmtLrL
18. M Malinowska FL Wilkinson KJ Langford-Smith, et al. 2010 Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease PLoS ONE 5 e14192 21152017 10.1371/journal.pone.0014192 1:CAS:528:DC%2BC3cXhsFGju7zF
19. M Matsuo N Sasaki K Saga T Kaneko 2005 Cytotoxicity of flavonoids toward cultured normal human cells Biol Pharm Bull 28 253 259 15684479 10.1248/bpb.28.253 1:CAS:528:DC%2BD2MXjtlyis7o%3D (Pubitemid 40880004)
20. PJ Medina S Goodin 2008 Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases Clin Ther 30 1426 1447 18803986 10.1016/j.clinthera.2008.08.008 1:CAS:528:DC%2BD1cXhtF2rtLfL
21. Neufeld EF, Muenzer J (2001) The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 3421-3452
22. E Piotrowska J Jakobkiewicz-Banecka S Baranska, et al. 2006 Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses Eur J Hum Genet 14 846 852 16670689 10.1038/sj.ejhg.5201623 1:CAS:528:DC%2BD28XmtVSmtrw%3D (Pubitemid 43923370)
23. E Piotrowska J Jakobkiewicz-Banecka A Tylki-Szymanska, et al. 2008 Genistin-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: an open-label, pilot study in 10 pediatric patients Curr Ther Res Clin Exp 63 166 179 10.1016/j.curtheres.2008.04.002 (Pubitemid 351834736)
24. E Piotrowska J Jakóbkiewicz-Banecka A Tylki-Szymańska B Czartoryska A Wȩgrzyn G Wȩgrzyn 2009 Correlation between severity of mucopolysaccharidoses and combination of the residual enzyme activity and efficiency of glycosaminoglycan synthesis Acta Paediatr 98 743 749 19046346 10.1111/j.1651-2227.2008.01153.x 1:CAS:528:DC%2BD1MXkvVWnt7k%3D
25. AL Roberts BJ Thomas AS Wilkinson JM Fletcher S Byers 2006 Inhibition of glycosaminoglycan synthesis using rhodamine B in a mouse model of mucopolysaccharidosis type IIIA Pediatr Res 60 309 314 16857766 10.1203/01.pdr.0000233037.00707.da 1:CAS:528:DC%2BD28XotlajtLs%3D (Pubitemid 44267744)
26. AL Roberts MH Rees S Klebe JM Fletcher S Byers 2007 Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA Mol Genet Metab 92 115 121 17681480 10.1016/j.ymgme.2007.06.016 1:CAS:528:DC%2BD2sXhtVWmt7fK (Pubitemid 47361897)
27. AL Roberts JM Fletcher L Moore S Byers 2010 Trans-generational exposure to low levels of rhodamine B does not adversely affect litter size or liver function in murine mucopolysaccharidosis type IIIA Mol Genet Metab 101 208 213 20650670 10.1016/j.ymgme.2010.06.008 1:CAS:528:DC%2BC3cXht1Cmtb%2FI
28. M Sanford LJ Scott 2009 Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer Drugs 69 2303 2328 19852530 10.2165/10489100-000000000-00000 1:CAS:528:DC%2BD1MXhsFOqtr%2FO
29. SI Sherman 2009 Tyrosine kinase inhibitors and the thyroid Best Pract Res Clin Endocrinol Metab 23 713 722 19942148 10.1016/j.beem.2009.08.001 1:CAS:528:DC%2BD1MXhsV2ktr3N
30. K Takeuchi F Ito 2010 EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors FEBS J 277 316 326 19922467 10.1111/j.1742-4658.2009.07450.x 1:CAS:528:DC%2BC3cXptVWisA%3D%3D
31. TH Tsai 2005 Concurrent measurement of unbound genistein in the blood, brain and bile of anesthetized rats using microdialysis and its pharmacokinetic application J Chromatogr A 1073 317 322 15909536 10.1016/j.chroma.2004.10.048 1:CAS:528:DC%2BD2MXjsVegt74%3D (Pubitemid 40544505)
32. G Wȩgrzyn J Jakóbkiewicz-Banecka M Narajczyk A Wiśniewski E Piotrowska M Gabig-Cimińska A Kloska M Słomińska-Wojewódzka A Korzon-Burakowska A Wȩgrzyn 2010 Why are behaviors of children suffering from various neuronopathic types of mucopolysaccharidoses different Med Hypotheses 75 605 609 20732748 10.1016/j.mehy.2010.07.044